Do Price Falls Make Banco Santander SA, Centrica PLC And GlaxoSmithKline plc Look Like Bargains?

Banco Santander SA (LON: BNC), Centrica PLC (LON: CNS) and GlaxoSmithKline plc (LON: GSK) are looking tempting.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

We usually hear much wailing when the FTSE 100 falls, and it’s down around 100 points today due to what’s happening in Greece. But those investing for the long term should rejoice and look for opportunities to pick up some bargain shares, and I’ve been checking out a few that could make for nice bargains now…

Banking

Banco Santander (LSE: BNC)(NYSE: SAN.US) shares have fallen 21% over the past 12 months, to 455p — and that comes after the bank has reversed its earnings decline, put in two years of strong growth, and is forecast to see EPS rise by 12% this year and 11% next. The dividend has been slashed, but that ended a crazy policy of paying very high dividends that were nowhere near covered by earnings, in the hope that people would take scrip instead of cash — we’re now looking at yields forecast of 2.9% and 3.3%.

The P/E would drop to 12.8 this year and 11.5% next, based on current expectations, which is a good bit below the FTSE average. But there is the fact that Santander is based in Spain, and there must be fears that Spain could go the way of Greece, so that’s possibly holding the price down.

Energy

A strong high-dividend utilities company can be a good one to have in your portfolio, and Centrica (LSE: CNA) fits the bill nicely. Its dividend is expected to drop a little this year, but should still yield around 4.4% — and the City is predicting a rise to 4.5% a year later.

But over the past year the share price has fallen 12% to 39p, and by 24% over two years. That’s partly justified by a fall to a lower lever of earnings on the back of plummeting oil prices and a competitive pricing squeeze, but the shares are still on a forward P/E of about 15 — and I think that’s good value for such a solid dividend payer.

Pills and potions

Finally I come to GlaxoSmithKline (LSE: GSK)(NYSE: GSK.US), whose shares are down 13% in a year — 2015 started out strongly, but since a peak in April the price has fallen back down to 1,359p. Our big FTSE 100 pharmaceuticals companies have been struggling to get back to earnings growth in recent years, and AstraZeneca was looking like the turnaround star for a while. But 2015 is expected to see the end of the slump for Glaxo with a 16% fall in EPS, and then a return to growth with a 10% rise pencilled in for 2016.

Dividend yields of better than 6% should only just be covered, but if we do get the likely growth return, the firm should be able to maintain them. On a 2016 P/E of 15.5 is Glaxo a comeback bargain? It could well be.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended Centrica and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »

Investing Articles

The JD Sports Fashion share price has just plunged another 16%! Buy or sell?

Harvey Jones is reeling after another sharp drop in the JD Sports Fashion share price. Should he seize the chance…

Read more »